Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial results evaluating safety, tolerability, and pharmacokinetics of an iloperidone depot formulation in patients with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Iloperidone Depot (iloperidone)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Schizophrenia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-10-08